Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 14, 2021

SELL
$53.8 - $81.53 $13,450 - $20,382
-250 Closed
0 $0
Q4 2020

Feb 16, 2021

SELL
$36.89 - $93.56 $6,271 - $15,905
-170 Reduced 40.48%
250 $21,000
Q3 2020

Nov 13, 2020

BUY
$23.13 - $38.84 $9,714 - $16,312
420 New
420 $15,000

Others Institutions Holding DNLI

About Denali Therapeutics Inc.


  • Ticker DNLI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 134,174,000
  • Market Cap $2.88B
  • Description
  • Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...
More about DNLI
Track This Portfolio

Track C M Bidwell & Associates LTD Portfolio

Follow C M Bidwell & Associates LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of C M Bidwell & Associates LTD, based on Form 13F filings with the SEC.

News

Stay updated on C M Bidwell & Associates LTD with notifications on news.